These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9346851)

  • 1. Subunit peptide cancer vaccines targeting activating mutations of the p21 ras proto-oncogene.
    Triozzi PL; Stoner GD; Kaumaya PT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):185-92. PubMed ID: 9346851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
    Schott ME; Wells DT; Schlom J; Abrams SI
    Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
    Peace DJ; Chen W; Nelson H; Cheever MA
    J Immunol; 1991 Mar; 146(6):2059-65. PubMed ID: 2005390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
    Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse.
    Pullano TG; Sinn E; Carney WP
    Oncogene; 1989 Aug; 4(8):1003-8. PubMed ID: 2474786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of monoclonal antibodies specific to the activated ras p21 with aspartic acid at position 13.
    La Vecchio JA; Hamer PJ; Ng SC; Trimpe KL; Carney WP
    Oncogene; 1990 Aug; 5(8):1173-8. PubMed ID: 2202949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
    Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
    Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid modifications in the wild type sequence p53 232-240 overcome the poor immunogenicity of this self tumour epitope.
    Baratin M; Kayibanda M; Ziol M; Romieu R; Briand JP; Guiller JG; Viguier M
    J Pept Sci; 2002 Jul; 8(7):327-34. PubMed ID: 12148782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
    Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cell recognition of a point mutation in the P21 Ras protein.
    Yin L; Lowe P; Stauss HJ
    Leukemia; 1993 Aug; 7 Suppl 2():S27-30. PubMed ID: 7689674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of activated Mr 21,000 protein, the product of ras oncogenes, using antibodies with specificity for amino acid 12.
    Wong G; Arnheim N; Clark R; McCabe P; Innis M; Aldwin L; Nitecki D; McCormick F
    Cancer Res; 1986 Dec; 46(12 Pt 1):6029-33. PubMed ID: 3490906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
    Kubuschok B; Neumann F; Breit R; Sester M; Schormann C; Wagner C; Sester U; Hartmann F; Wagner M; Remberger K; Schilling M; Pfreundschuh M
    Clin Cancer Res; 2006 Feb; 12(4):1365-72. PubMed ID: 16489095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model.
    Adnane J; Jackson RJ; Nicosia SV; Cantor AB; Pledger WJ; Sebti SM
    Oncogene; 2000 Nov; 19(47):5338-47. PubMed ID: 11103935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.